Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The role of B cells in central nervous system (CNS) autoimmunity was initially highlighted by successful clinical trials of anti-CD20 monoclonal antibodies in multiple sclerosis (MS). Research in MS as well as in aquaporin 4 (AQP4)-IgG neuromyelitis optica (NMO) and myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorder (MOGAD) has expanded our appreciation of the contribution of B cells in multiple CNS autoimmune diseases. B cells have multiple functions in the initiation and propagation of CNS autoimmunity that extend beyond autoantibody production, including bidirectional interactions with T cells via B-cell antigen presentation. A deeper understanding of the cooperation between B cells and T cells in MS, NMO, and MOGAD should permit the development of more effective therapies across CNS autoimmune disorders.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.coi.2025.102647 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel Prognostic Scoring Systems for Severe CRS after Anti-CD19 CAR-T-Cells in Acute B-Lymphoblastic Leukemia.
Curr Med Sci
September 2025
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Objective: To develop a novel prognostic scoring system for severe cytokine release syndrome (CRS) in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with anti-CD19 chimeric antigen receptor (CAR)-T-cell therapy, aiming to optimize risk mitigation strategies and improve clinical management.
Methods: This single-center retrospective cohort study included 125 B-ALL patients who received anti-CD19 CAR-T-cell therapy from January 2017 to October 2023. These cases were selected from a cohort of over 500 treated patients on the basis of the availability of comprehensive baseline data, documented CRS grading, and at least 3 months of follow-up.
Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus.
Cytotherapy
July 2025
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy. Electronic address:
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of aggressive B-cell non-Hodgkin lymphoma, particularly in relapsed/refractory large B-cell lymphoma and mantle cell lymphoma. Despite its transformative potential, significant challenges persist in optimizing patient identification and referral pathways to ensure timely and equitable access. This expert consensus, developed through the Delphi methodology, analyzes key barriers to the referral process and proposes structured solutions to enhance collaboration between referring treatment centers (RTCs) and qualified treatment centers (QTCs).
View Article and Find Full Text PDFFrom Trials to Practice: A 2025 Review of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel Efficacy Across Clinical Studies and Real-World Evidence.
Eur J Haematol
September 2025
Department of Hematology-Oncology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies have revolutionized the approach and management of relapsed/refractory multiple myeloma (RRMM), and as of 2025, idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are the only BCMA-targeted CAR T-cell therapies approved by the FDA. Exceptional responses were demonstrated for heavily pretreated patients in the KarMMa-1 trial, reporting a 73% overall response rate (ORR) and 98% in the CARTITUDE-1 trial. Furthermore, both therapies show a significant improvement in progression-free survival (PFS) compared to standard regimens when administered in earlier lines.
View Article and Find Full Text PDFEngrafted NSG-SGM3 humanized mice spontaneously produce human immunoglobulins including IgE.
Front Immunol
September 2025
Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
NSG-SGM3 humanized mouse models are well-suited for studying human immune physiology but are technically challenging and expensive. We previously characterized a simplified NSG-SGM3 mouse, engrafted with human donor CD34 hematopoietic stem cells without receiving prior bone marrow ablation or human secondary lymphoid tissue implantation, that still retains human mast cell- and basophil-dependent passive anaphylaxis responses. Its capacities for human antibody production and human B cell maturation, however, remain unknown.
View Article and Find Full Text PDFThe effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy.
Blood Cell Ther
August 2025
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Background: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment landscape for relapsed or refractory non-Hodgkin lymphoma, achieving a 5-year overall survival rate of 40-50%. However, relapse remains a major challenge, especially due to CD19-negative clones. Epcoritamab, a bispecific antibody targeting CD20 and CD3, offers a potential solution for post-CAR-T relapse; however, clinical data in this setting remain limited, particularly in Japan.
View Article and Find Full Text PDF